United Kingdom· GB-APID-40606811000001109
Givlaari 189mg/1ml solution for injection vials
A givosiran product containing givosiran, registered in United Kingdom by Alnylam UK Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Givosiran is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AX16 (givosiran), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Givosiran · ATC A16AX16
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Givosiran
- Manufacturer
- Alnylam UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- A16AX16
- ATC class
- Givosiran
- Defined daily dose
- 5.8 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin08720165814152
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
105 interactions on record for givosiran.
Graded by severity as the source publishes them — 24 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Givosiran · interactions on record
105 records
- 24 severe
- 81 moderate
Most severe, free to view
- EliglustatA16AX10severe
- TemsirolimusL01EG01severe
- EverolimusL01EG02severe
- SirolimusL01EG04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Givosiran in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaGIVLAARIALNYLAM NETHERLANDS B.V.
- SwitzerlandGivlaari
- SpainGIVLAARI 189 MG/ML SOLUCION INYECTABLEAlnylam Netherlands B.V.
- FranceGIVLAARI 189 mg/mL, solution injectableALNYLAM NETHERLANDS (PAYS-BAS)
- IcelandGivlaariAlnylam Netherlands B.V.
- NetherlandsGivlaari 189 mg/ml oplossing voor injectieAlnylam Netherlands B.V.
- PolandGivlaariAlnylam Netherlands B.V.
- SwedenGivlaari 189 mg/ml Injektionsvätska, lösningAlnylam Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Givlaari
- Liechtenstein · Givlaari
- Norway · Givlaari
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f0789a1f-efe8-4446-ad03-2b0e762be23a GET /v1/drugs/f0789a1f-efe8-4446-ad03-2b0e762be23a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "40606811000001109",
"desc": "Givlaari 189mg/1ml solution for injection vials (Alnylam UK Ltd)",
"form": "Solution for injection",
"vpid": "40609011000001109",
"source": "dmd",
"vtm_id": "830241006",
"strength": "189 mg",
"substance": "Givosiran",
"ingredient": "Givosiran sodium",
"supplier_code": "37334111000001102"
}See everything about givosiran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.